TRAVERE THERAPEUTICS, INC. Additional Paid in Capital
TRAVERE THERAPEUTICS, INC. (TVTX) had Additional Paid in Capital of $1.57 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital $1.57B.
- 2026-03-31: Additional Paid in Capital $1.61B.
- 2025-12-31: Additional Paid in Capital $1.59B.
- 2025-09-30: Additional Paid in Capital $1.55B.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $1.57B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $1.61B 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $1.59B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.55B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $1.53B 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $1.52B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $1.51B 10-K · filed 2026-02-19 | |
| 2024-09-30 | $1.36B 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.35B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $1.34B 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $1.33B 10-K · filed 2025-02-21 | |
| 2023-09-30 | $1.32B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.31B 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $1.29B 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $1.06B 10-K · filed 2024-02-20 | |
| 2022-09-30 | $1.05B 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $1.04B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.02B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $1.07B 10-K · filed 2023-02-23 | |
| 2020-12-31 | $797.99M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $636.91M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $589.79M 10-K · filed 2020-02-24 | |
| 2017-12-31 | $471.80M 10-K · filed 2019-02-26 | |
| 2016-12-31 | $421.31M 10-K · filed 2018-07-06 | |
| 2015-12-31 | $365.80M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $140.85M 10-K · filed 2016-02-26 | $140.85M 10-K · filed 2015-03-11 |
| 2014-06-30 | $133.45M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $105.37M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $49.64M 10-K · filed 2015-03-11 | $50.19M 10-K · filed 2014-03-28 |
| 2013-09-30 | $46.22M 10-Q/A · filed 2015-07-09 | $48.65M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $34.94M 10-Q · filed 2013-09-16 | |
| 2013-03-31 | $34.77M 10-Q/A · filed 2013-09-16 | $35.13M 10-Q · filed 2013-07-24 |
| 2012-12-31 | $30.20M 10-Q/A · filed 2015-07-09 | |
| 2012-11-30 | $81.99K 10-Q · filed 2013-03-06 | |
| 2012-08-31 | $78.99K 10-Q · filed 2012-10-10 | |
| 2012-05-31 | $75.99K 10-Q · filed 2012-08-08 | |
| 2012-02-29 | $72.99K 10-Q · filed 2013-03-06 | |
| 2011-12-31 | $2.77M 10-K/A · filed 2013-09-16 | |
| 2011-11-30 | $66.90M 10-Q · filed 2012-01-11 | |
| 2011-02-28 | $60.90K 10-Q/A · filed 2012-06-06 | $60.90M 10-Q · filed 2012-01-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |